Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

24.01.2020 | special report | Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020

The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2020
Autoren:
M.D. Prof. Helmut H. Popper, Ulrike Gruber-Mösenbacher, Georg Pall, Leonhard Müllauer, Maximilian Hochmair, Dagmar Krenbek, Luka Brcic, Katja Schmitz, Bernd Lamprecht, Josef Eckmayr, Wolfgang Hilbe, Georg Hutarew, Peter Errhalt, Rainer Kolb, Robert Pirker, Ulrike Setinek, Gerald Webersinke, Gudrun Absenger, Tamara Hernler, Markus Rauter, Richard Wasicky
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

The knowledge on molecular alterations in lung cancer have increased during the last decade considerably. Almost every year new genes were detected being targetable, and drugs have been developed and provided for those patients being diagnosed with such a lung cancer. Therefore, it was necessary to update previous recommendations to facilitate a uniform handling for the diagnosis and molecular tests of lung cancer specimen all over Austria. Originally mutation of the epidermal growth factor receptor (EGFR) was the only actionable molecular alteration, now there are more than 10 driver mutations known, and more are detected, and clinical studies are performed. In addition, the technique to test for these mutations have improved, next generation sequencing has opened the option to test several genes in one test. Immuno-oncology has entered the field, and besides the checkpoint death receptor and ligand molecules PD-1/PD-L1 more molecules have been detected and are also tested in clinical studies.
To provide equal opportunities to our patients the tests have to be implemented in all pathological institutes involved in lung cancer management. Because pathologists as part of the tumor board have to explain the diagnosis and the molecular alterations and suggest possible treatment options, the tests should be performed in-house, which will provide the optimal quality control.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2020

memo - Magazine of European Medical Oncology 1/2020 Zur Ausgabe